Marianne Pape1, Helle D Zacho2,3, Jens Aarøe1, Svend Eggert Jensen1,3, Lars J Petersen2,3. 1. a The Department of Cardiology , Aalborg University Hospital , Aalborg , Denmark ; 2. b The Department of Nuclear Medicine , Aalborg University Hospital , Aalborg , Denmark ; 3. c The Department of Clinical Medicine , Aalborg University , Aalborg , Denmark.
Abstract
OBJECTIVES: Evaluating safety and tolerability of the selective A2A receptor agonist, regadenoson, in patients referred for single photon emission computed tomography myocardial perfusion imaging (MPI). DESIGN: Observational study of patients referred for MPI stress testing using a 400 μg regadenoson (Rapiscan(®)) bolus. Hemodynamic variables and severity of adverse events (AE) were recorded before, during, and after administration. RESULTS: A total of 232 patients were included. One or more AE were reported in 90% of patients; the AEs were graded mostly mild to moderate in severity, resolved spontaneously, and were mainly dyspnea, headache, and chest pain. No advanced heart block or bronchospasm were seen. Transient ST-segment changes developed in 10 patients. The maximum increase in heart rate was 19 ± 11 beats/minute. The mean systolic blood pressure decreased from 144 to 139 mmHg (p < 0.0001). Medical intervention was required in three patients: one case with severe hypotension and two cases with chest pain that was relieved with sublingual nitroglycerin. One patient died the day after stress MPI for reasons considered unrelated to regadenoson. CONCLUSION: Regadenoson for MPI is easy to use with a high frequency of AEs, which are generally mild in severity, transient, and resolve spontaneously.
OBJECTIVES: Evaluating safety and tolerability of the selective A2A receptor agonist, regadenoson, in patients referred for single photon emission computed tomography myocardial perfusion imaging (MPI). DESIGN: Observational study of patients referred for MPI stress testing using a 400 μg regadenoson (Rapiscan(®)) bolus. Hemodynamic variables and severity of adverse events (AE) were recorded before, during, and after administration. RESULTS: A total of 232 patients were included. One or more AE were reported in 90% of patients; the AEs were graded mostly mild to moderate in severity, resolved spontaneously, and were mainly dyspnea, headache, and chest pain. No advanced heart block or bronchospasm were seen. Transient ST-segment changes developed in 10 patients. The maximum increase in heart rate was 19 ± 11 beats/minute. The mean systolic blood pressure decreased from 144 to 139 mmHg (p < 0.0001). Medical intervention was required in three patients: one case with severe hypotension and two cases with chest pain that was relieved with sublingual nitroglycerin. One patient died the day after stress MPI for reasons considered unrelated to regadenoson. CONCLUSION:Regadenoson for MPI is easy to use with a high frequency of AEs, which are generally mild in severity, transient, and resolve spontaneously.
Authors: Johannes Uhlig; Christian Lücke; Rozemarijn Vliegenthart; Christian Loewe; Matthias Grothoff; Andreas Schuster; Philipp Lurz; Alexis Jacquier; Marco Francone; Antonia Zapf; Christoph Schülke; Matthias Stefan May; Jens Bremerich; Joachim Lotz; Matthias Gutberlet Journal: Eur Radiol Date: 2019-04-30 Impact factor: 5.315
Authors: Jose V Monmeneu Menadas; Maria P García Gonzalez; Maria P Lopez-Lereu; Laura Higueras Ortega; Alicia M Maceira Gonzalez Journal: Int J Cardiovasc Imaging Date: 2021-07-31 Impact factor: 2.357